Zacks Bull & Bear of the Day Highlights: InterDigital, Overstock.com, Sanofi-Aventis, Bristol-Myers Squibb and Biogen Idec

Zacks Bull & Bear of the Day Highlights: InterDigital, Overstock.com, Sanofi-Aventis, Bristol-Myers Squibb and Biogen IdecCHICAGOIL-ZACKS.COM

Zacks Equity Research picks InterDigital Inc. (Nasdaq: IDCC) as Bull of the Day and Overstock.com (Nasdaq: OSTK) as Bear of the Day. In addition, the analysts at Zacks Equity Research discuss the latest on Sanofi-Aventis (NYSE: SNY), Bristol-Myers Squibb (NYSE: BMY) and Biogen Idec (Nasdaq: BIIB).

Full analysis of all these stocks is available at: http://at.zacks.com/?id=2678

Bull of the Day

We upgrade our rating to Buy with a higher valuation target for InterDigital Inc. (Nasdaq: IDCC), a leading wireless technology and licensing company. This follows the settlement of a patent licensing dispute with Samsung Electronics which further strengthens InterDigital?s cash position in addition to reducing royalty related litigation expenses in future reporting periods.

Furthermore, management raised its fourth quarter revenue guidance as a result of an increase in non-recurring revenue. InterDigital continues to undertake effective cost control measures.

We believe the company has a sound business model, a firm financial position, and maintains a strong technological base as it contends with challenging economic conditions.

Bear of the Day

Overstock.com (Nasdaq: OSTK) managed to turn a profit for the fourth quarter, but we were less than impressed. The company received a one-time gain of $1.8 million to its gross profit that enabled the company to report a $0.04 per share profit instead of a loss of $0.04 per share.

In addition, the company?s sales declined 13% year-over-year. This decline was due in large part to management cutting its marketing spend by 40%. The company plans to keep those marketing costs steady, and that will produce flat to down sales for the company in 2009.

Meanwhile, Overstock.com will be ramping up its technology and general and admin expenses. In our view, this will result in a revenue decline of 2% and a larger of net loss of $0.74 per share. We reiterate our Sell rating and lower our target price from $7 to $5.

Recent Analysis from the Analyst Blog

Sanofi Eyeing Major Acquisition

Unconfirmed rumors have been circulating since last week that Sanofi-Aventis (NYSE: SNY), the world?s 4th largest pharmaceutical company, is considering a major acquisition. In fact, sources at the Financial Times say the French drug maker is speaking with investment banks about raising as much as $25 billion in cash.

The first name that immediately comes to mind as a potential target for Sanofi-Aventis is Bristol-Myers Squibb (NYSE: BMY). The duo collaborated on blood thinner Plavix and blood pressure drug Avapro through 50/50 joint ventures. Plavix is the world?s second largest selling drug behind Pfizer?s cholesterol drug Lipitor.

Another name that comes to mind is biotech bellwether, Biogen Idec (Nasdaq: BIIB). The deal would be significantly less expensive for Sanofi, and offer one-stop broad move squarely into biologics. For Sanofi, with already significant manufacturing capacity and expertise in vaccine development, acquiring Biogen would give it one of the world?s largest biologic manufacturing footprints, along with several late-stage biologic candidates for inflammatory disease and cancer.

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.